Madrigal Pharmaceuticals, Inc. (MDGL) › Cost of RevenueMadrigal Pharmaceuticals, Inc. (MDGL): Cost of RevenueAnnual figures by period end, from SEC filings.$6.23MYear ended 2024-12-312022-12-31: $02023-12-31: $02024-12-31: $6.23M$6.23M2022-12-31 Cost of Revenue (USD) 2024-12-31Period endedCost of RevenueChange YoYSource filing2024-12-31$6.23Mn/a2025-02-26, From 2024-01-012023-12-31$0n/a2025-02-26, From 2023-01-012022-12-31$0n/a2025-02-26, From 2022-01-01Other metrics: RevenueR&D ExpenseOperating IncomeDepreciation & AmortizationEBITDANet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesLong-Term DebtShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresFree Cash FlowShare RepurchasesShares OutstandingWeighted Average Diluted SharesEPS (Basic)